2,5-dioxopyrrolidin-1-yl 1H-indole-2-carboxylate | 124946-98-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 2,5-dioxopyrrolidin-1-yl 1H-indole-2-carboxylate
• 英文别名: Succinimido indolecarboxylate；(2,5-dioxopyrrolidin-1-yl) 1H-indole-2-carboxylate
• CAS: 124946-98-1
• 化学式: C₁₃H₁₀N₂O₄
• 分子量: 258.233
• InChiKey: WZLYEHCTERUYTR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  19
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.15
• 拓扑面积：
  79.5
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  2,5-dioxopyrrolidin-1-yl 1H-indole-2-carboxylate 在 N,N-二异丙基乙胺 、 Methanaminium,N-[(dimethylamino)(3H-1,2,3-triazolo[4,5-b]pyridin-3-yloxy)methylene]-N-methyl-, hexafluorophosphate(1-) 作用下， 以 乙醇 、 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 生成 N-[(2S)-1-[(1R,2S,5S)-2-{[(1S)-1-carbamoyl-2-[(3S)-2-oxopyrrolidin- 3-yl]ethyl]carbamoyl}-1,5-dihydrogenio-6,6-dimethyl-3-azabicyclo[3.1.0]hexan-3-yl]-4-methyl-1- oxopentan-2-yl]-1H-indole-2-carboxamide
  参考文献：
  名称：

  [EN] PROTEASE INHIBITORS AS ANTIVIRALS
  [FR] INHIBITEURS DE PROTÉASE UTILISÉS COMME ANTIVIRAUX

  摘要：

  本文提供了与治疗由冠状病毒或肠道病毒引起的病毒感染相关的化合物、药物组合物和治疗方法。本文提供了公式(I)、(II)和(III)化合物以及使用这些化合物进行治疗的方法。这些化合物是肽类模拟物，能够抑制冠状病毒的蛋白酶3CL，并且可用于治疗由病毒感染引起的疾病，包括COVID-19。

  公开号：

  WO2022256434A1
• 作为产物：
  描述：

  N-羟基丁二酰亚胺 、 吲哚-2-羧酸 在 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 作用下， 以 二氯甲烷 为溶剂， 生成 2,5-dioxopyrrolidin-1-yl 1H-indole-2-carboxylate
  参考文献：
  名称：

  铜催化N-羟基琥珀酰亚胺酯与异氰基乙酸酯的[3+2]环加成反应合成4,5-二取代恶唑

  摘要：

  描述了铜催化的N-羟基琥珀酰亚胺酯与异氰酸根乙酸酯的环加成反应。以中高产率获得了一系列 4,5-二取代恶唑化合物，包括衍生自天然脂肪酸、药物、氨基酸和肽的化合物。探索了衍生化反应。讨论了反应机理。

  DOI：

  10.1021/acs.joc.2c03084

文献信息

• Benzolactam compounds and pharmaceutical uses thereof
  申请人：Yoshitomi Pharmaceutical Industries Ltd.

  公开号：US05055464A1

  公开（公告）日：1991-10-08

  Benzolactam compounds of the general formula ##STR1## or isomers thereof as well as salts thereof inclusive of hydrates and/or solvates forms thereof, and benzolactam compounds of the general formula ##STR2## wherein each of the symbols is as defined in the specification. The compound (I) exhibit antiamnesic activity, and are useful as brain function-improving drugs. The compounds (a) and (b) are useful as an intermediate for said compounds (I). Futher, the compound (a) show diuretic or antiulcer activity, and are useful as a diuretic or antiulcer agent.

  苯并内酰胺化合物，其通式为##STR1##或其异构体以及包括水合物和/或溶剂化物形式的盐，以及通式为##STR2##的苯并内酰胺化合物，其中各个符号的定义如说明书中所述。化合物(I)显示出抗遗忘活性，并可作为改善脑功能的药物。化合物(a)和(b)可作为制备上述化合物(I)的中间体。此外，化合物(a)显示出利尿或抗溃疡活性，并可作为利尿剂或抗溃疡剂。
• [EN] MPRO CYSTEINE PROTEASE INHIBITORS<br/>[FR] INHIBITEURS DE CYSTÉINE PROTÉASE MPRO
  申请人：ANIXA BIOSCIENCES INC

  公开号：WO2022040186A1

  公开（公告）日：2022-02-24

  Described herein are Mpro cysteine protease inhibitors and methods of utilizing such inhibitors in the treatment of diseases, disorders, or conditions. Also described herein are pharmaceutical compositions containing such compounds.

  本文描述了Mpro半胱氨酸蛋白酶抑制剂及其在治疗疾病、疾病或状况中的应用方法。本文还描述了含有这些化合物的药物组合物。
• Development of potent and selective CCK-A receptor agonists from Boc-CCK-4: tetrapeptides containing Lys(N.epsilon.)-amide residues
  作者：Kazumi Shiosaki、Chun Wel Lin、Hana Kopecka、Richard A. Craig、Bruce R. Bianchi、Thomas R. Miller、David G. Witte、Michael Stashko、Alex M. Nadzan

  DOI：10.1021/jm00089a010

  日期：1992.5

  A series of Boc-CCK-4 derivatives represented by the general structure Boc-Trp-Lys(N(epsilon)-COR)-Asp-Phe-NH2, where R is an aromatic, heterocyclic, or aliphatic group, are potent and selective CCK-AT receptor agonists. These amide-bearing compounds complement the previously described urea-based tetrapeptides (Shiosaki et al. J. Med. Chem. 1991, 34, 2837-2842); structure-activity studies revealed parallel as well as divergent trends between these two series. A significant correlation was observed between pancreatic binding affinity and the resonance constant R of the phenyl substituent in one particular series of derivatives. Sulfation of phenolic amides appended onto the epsilon-amino group of the lysine did not affect affinity for the CCK-AT receptor in contrast to the 500-fold increase in binding potency observed upon sulfation of CCK-8, suggesting that the lysine appendage and the sulfated tyrosine in CCK-8, both key structural elements that impart high affinity for the CCK-A receptor, are interacting differently with the receptor. The amide-bearing tetrapeptides are full agonists relative to CCK-8 in stimulating pancreatic amylase release while being partial agonists in eliciting phosphoinositide (PI) hydrolysis. Both effects were blocked by selective CCK-A receptor antagonists.
• Pirotte, B.; Tullio, P. du; Neven, P., Bulletin des Societes Chimiques Belges, 1997, vol. 106, # 12, p. 781 - 790
  作者：Pirotte, B.、Tullio, P. du、Neven, P.、Dewalque, D.、Delarge, J.、et al.

  DOI：——

  日期：——
• US5055464A
  申请人：——

  公开号：US5055464A

  公开（公告）日：1991-10-08